Key result
Chronic infusion of atrial natriuretic peptide at 1.0 µg/h significantly reduced mean pulmonary arterial pressure by 9.3 mmHg in rats adapted to chronic hypoxia.
Why the study?
Does chronic infusion of atrial natriuretic peptide attenuate the development of pulmonary hypertension in rats adapted to chronic hypoxia?
Population
55 male Sprague-Dawley rats at 8 weeks of age, divided into normoxic and hypoxic exposure groups.
Comparison
Atrial natriuretic peptide 0.2 or 1.0… vs 0.1 M acetic acid vehicle continuous intravenous…
Design
Preclinical
Follow-up
4 weeks
Authors
Loading...
Extends preclinical evidence for natriuretic peptides in hypoxia-induced pulmonary hypertension; leaves open human translation.
Does chronic infusion of atrial natriuretic peptide attenuate the development of pulmonary hypertension in rats adapted to chronic hypoxia?
Mean Difference: -9.3
Absolute Event Rate: 24.6% vs 33.9%
p-value: p=<0.01
Chronic infusion of exogenous atrial natriuretic peptide attenuates the development of pulmonary hypertension and right ventricular enlargement in a rat model of chronic hypoxia.
Jin et al. (1990) studied Hypoxia-induced pulmonary hypertension (n=55). Atrial natriuretic peptide (ANP) vs. Vehicle (0.1 M acetic acid) was evaluated on Mean pulmonary arterial pressure (MPAP) (MD -9.3 mmHg, p=<0.01). Chronic infusion of atrial natriuretic peptide at 1.0 µg/h significantly reduced mean pulmonary arterial pressure by 9.3 mmHg in rats adapted to chronic hypoxia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: